Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Preferred Stock Liabilities (2022 - 2023)

Standard Biotools (LAB) has disclosed Preferred Stock Liabilities for 3 consecutive years, with $311.3 million as the latest value for Q4 2023.

  • Quarterly Preferred Stock Liabilities changed 0.0% to $311.3 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $311.3 million through Dec 2023, changed 0.0% year-over-year, with the annual reading at $311.3 million for FY2023, 0.0% changed from the prior year.
  • Preferred Stock Liabilities for Q4 2023 was $311.3 million at Standard Biotools, roughly flat from $311.3 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $311.3 million in Q2 2022, with the low at $311.3 million in Q2 2022.